1.
Antimicrob Agents Chemother
; 68(7): e0029024, 2024 Jul 09.
Artículo
en Inglés
| MEDLINE
| ID: mdl-38809000
RESUMEN
We report the emergence of cefiderocol resistance in a blaOXA-72 carbapenem-resistant Acinetobacter baumannii isolate from a sacral decubitus ulcer. Cefiderocol was initially used; however, a newly approved sulbactam-durlobactam therapy with source control and flap coverage was successful in treating the infection. Laboratory investigation revealed cefiderocol resistance mediated by ISAba36 insertion into the siderophore receptor pirA.